Pharmaceutical companies approach a significant wave of patent expirations by 2030. This includes exclusivity rights set to expire for 569 medications valued at $278 billion, based on 2022 sales.¹ As ...
Established brands represent the majority of portfolios across pharma’s global affiliates that are often neglected, with revenue and profit growth untapped. In the coming period, pharma should witness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback